Abstract
Enterprise architecture (EA) is useful for effectively structuring digital platforms with digital transformation in information societies. Moreover, digital platforms in the healthcare industry accelerate and increase the efficiency of drug discovery and development processes. However, there is the lack of knowledge concerning relationships between EA and digital platforms, in spite of the needs of it. In this paper, we investigated and analyzed the process of drug design and development within the healthcare industry, together with related work in using an enterprise architecture framework for the digital era named the Adaptive Integrated Digital Architecture Framework (AIDAF), specifically supporting the design of digital platforms there. Based on this analysis, we evaluate a method and propose a new reference architecture for promoting digital platforms in the healthcare industry, with future specific aspects of them making effective use of Artificial Intelligence (AI). The practical and theoretical contributions include: (1) Streamlined processes through digital platforms in organizations. (2) Informal knowledge supply and sharing among organizational members through digital platforms. (3) Efficiency and effectiveness in planning production and business for drug development. The findings indicate that EA with digital platforms using the AIDAF contribute to digital transformation with effectiveness for new drugs in the healthcare industry.
Highlights
Introduction published maps and institutional affilWe consider new enhancements of business structure and process efficiency using digital platforms such as portals and social networking services (SNSs) among corporations in healthcare industries
Digital platforms correlated with the artificial intelligence and intermediary knowledge model, the search extended to Enterprise architecture (EA) with digital platforms in relation to healthcare ecosystems
The above data analytics functions for reviews with artificial intelligence (AI) components in the new drug development plan review system on the drug development platform can show effectiveness of correctness and comprehensiveness in terms of each expertise area as described in Section 5.2.3, and the above new drug development plan review system of that platform can enhance the efficiency in planning new drug developments and business with the assumed 40% improvement as the number of necessary actions and the expected
Summary
We consider new enhancements of business structure and process efficiency using digital platforms such as portals and social networking services (SNSs) among corporations in healthcare industries. We expect the use of these digital platforms for drug discovery and development processes in pharmaceutical companies at the forefront of the recent utilization of digital IT technologies. How to properly use these digital platforms for drug discovery and development processes within pharmaceutical companies is still not well understood. The enterprises and information societies in healthcare industries have confronted various changes, such as globalization, shifts in customer needs, and new business models with emerging technologies, whose significant changes due to recent developments in cloud computing, mobile IT, and big data technology have appeared as new information technology trends. Aforementioned technologies making advances and related iations
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
